Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704.